22.52
0.13%
+0.03
Exelixis Inc stock is currently priced at $22.52, with a 24-hour trading volume of 2.18M.
It has seen a +0.13% increased in the last 24 hours and a -4.05% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $22.73 pivot point. If it approaches the $22.23 support level, significant changes may occur.
Exelixis Inc Stock (EXEL) Financials Data
Exelixis Inc (EXEL) Revenue 2024
EXEL reported a revenue (TTM) of $1.83 billion for the quarter ending December 31, 2023, a +13.60% rise year-over-year.
Exelixis Inc (EXEL) Net Income 2024
EXEL net income (TTM) was $207.76 million for the quarter ending December 31, 2023, a +13.98% increase year-over-year.
Exelixis Inc (EXEL) Cash Flow 2024
EXEL recorded a free cash flow (TTM) of $170.35 million for the quarter ending December 31, 2023, a -24.00% decrease year-over-year.
Exelixis Inc (EXEL) Earnings per Share 2024
EXEL earnings per share (TTM) was $0.6433 for the quarter ending December 31, 2023, a +12.86% growth year-over-year.
Exelixis Inc Stock (EXEL) Latest News
What Analysts Are Saying About Exelixis Stock
Benzinga
EXEL or REGN: Which Is the Better Value Stock Right Now?
Zacks Investment Research
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The Motley Fool
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Zacks Investment Research
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Zacks Investment Research
2 Biotech Stocks to Buy Hand Over Fist in March
The Motley Fool
About Exelixis Inc
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):